41st Pharmacovigilance USA 2026
41st Pharmacovigilance USA 2026
27 & 28 May, 2026
Boston, USA
5 Reasons to attend the event
Knowledge
Gain insights from experts, researchers, and professionals to stay updated on the latest pharma advancements.
An Agenda Made For You
High quality content that addresses your biggest challenges and uncovering hidden opportunities.
Cutting-Edge Insights
Discover the latest trends, innovations, and breakthroughs shaping the future of the pharmaceutical industry.
Networking
Connect with peers, industry leaders, and collaborators to exchange ideas and explore new opportunities.
Practical Takeaways
Walk away with actionable strategies, real-world case studies, and learn best practices to implement in your work.
Knowledge
Gain insights from experts, researchers, and professionals on the latest pharma advancements.
An Agenda Made For You
High quality content that addresses your biggest challenges and uncovering hidden opportunities.
Cutting-Edge Insights
Explore the latest trends, innovations, and breakthroughs driving the future of the pharmaceutical industry.
Networking
Connect with peers, industry leaders, and collaborators to exchange ideas and explore new opportunities.
Practical Takeaways
Walk away with practical strategies, case studies, and proven best practices to apply in real-time.
Key Focus Areas
Event Speakers
Download Brochure
Event Schedule
Meet to learn and network with your conference colleagues.
09:00 - Chairperson opening remarks
Speaker
BEN LOCWIN
VP Board of Directors
SOPPhC (VP, Reliant Life Sciences)
09:10 – AI Agents Transforming Safety, Reporting, and Operations
DATA TO DECISIONS
- Medical AI Agent for Adverse Event Assessment
- From Data to Draft: A Proof-of-Concept Agent for AI – Assisted Aggregate Report Writing
- An AI Agent for Intelligent Navigation of Company Procedures
Speaker
PRIYANKA CHHIKARA
Head of Risk Management, Aggregate Reports & Data
Science, CSL Behring
VINEET SINGH
Head of PV Data Science and Analytics
CSL Behring
09:40 – Product safety reviews – purpose & function
SAFETY
- What to look for in signal evaluation under new EU guidance
- Developing drug safety signals for report quality and content
- Timings for safety review in clinical and post marketed products
- Validation and confirmation of risk and benefits from signal received
- Record keeping for safety review meetings
Speaker
RUDI SCHEERLINCK
Safety Strategy Lead – Oncology
Healthcare Business of Merck
10:10 – Keynote Panel Discussion: Reimagining Global Pharmacovigilance: From Today’s Challenges to Tomorrow’s Solutions
CHALLENGES & OPPORTUNITIES
Moderator
MARIETTE BOERSTOEL-STREEFLAND
SVP, Worldwide Patient Safety Officer
Bristol-Myers Squibb
Panellists
PHILISHA MACK
Sr. Director of Drug Safety, Medical Affairs
Azurity Pharmaceuticals
NICOLE SCHUMACHER-CROW
Continuous Improvement Center of Excellence Head
– Senior Director, Pfizer
MILIND SARDESA
Executive Director, Safety Surveillance, Global
Patient Safety, Dicerna Pharmaceuticals
VASUDEV BHUPATHI
Director – Pharmacovigilance
Moderna
NAMITA JOSHI
Regional PV Head, North America
Sanofi
11:00 – Morning Networking Coffee/Tea & Discussion
11:30 – Real World Data to Real World Evidence
RWD / RWE
- Importance of real-world data for answering regulatory questions
- Benefits and challenges of evidence derived from real world sources
- Real World Evidence: How Does its Use challenge quality and compliance programs?
- Obtaining patient-centric using RWE
- What are complications that will rise by inserting new data source? Breakup in data?
- Identify the challenges involved in incorporating real world evidence into a structured benefit-risk assessment.
JULIE BARBERIO
Director, Pharmacoepidemiology
Sanofi
12:00 – Solution Provider Presentation
For sponsorship opportunities please contact
info.uk@virtueinsight.com
JULIE BARBERIO
Director, Pharmacoepidemiology
Sanofi
12:30 – Networking luncheon
13:30 – Panel Discussion - Transforming Pharmacovigilance Through Technology: AI, Automation, and the Future of Drug Safety. Opportunities, Challenges & Lessons Learned
IMPACT OF TECHNOLOGY
Moderator
HEATHER LEIGH FLANNERY
CEO & Co-Founder
AI MINDSystems Foundation
Panellists
ALTON SARTOR
Medical Director, Patient Safety Physician Digital &
Devices, AstraZeneca
PRIYANKA CHHIKARA
Head of Risk Management, Aggregate Reports &
Data Science, CSL Behring
MICHAEL VON FORSTNER
Chief Scientific Officer
MedGenie
CINTHYA GALICIA QUINTANAR
Senior Manager, Country Safety Lead
Pfizer
14:20 – From Compliance to Excellence: The future of Patient Safety
COMPLIANCE
- Patient Safety, where are we and what has changed lately?
- Fundamentals remain unchanged
- Shift the focus
- Implementation strategy
- Conclusion and take aways
Speaker
MALIN KREITZ
Director of European Operations
Ultragenic Research and Technologies
14:50 – Gene therapy, long-term follow-up, and Inspection readiness
GENE THERAPY / INSPECTION
- Long-term follow-up requirements for Gene therapy
- How to plan inspection readiness activities for Gene therapy.
- Risk Management in Gene Therapy
Speaker
KAPIL BHUTADA
Head of PV Safety Operation & Compliance
Asklepios BioPharmaceutical
15:20 - Afternoon Networking Coffee/Tea & Discussion
15:50 – The round table series
COLLABRATIVE BREAKOUT SESSIONS
Chairperson for all tables
Speaker
BEN LOCWIN
VP Board of Directors
SOPPhC (VP, Reliant Life Sciences)
We have curated 6 distinct roundtable topics, each led by an 2 table speakers. The session is designed for maximum cross-pollination of ideas.
The Selection: Look at the table numbers and topics listed below. Choose the theme most relevant to your interest.
The Format: Each table will host a focused, 60-minute deep dive.
The Flow: Take a seat at your first chosen table. The table speakers will kick off with a brief prompt followed by an open-floor discussion. You have the option to stay put to go deeper or rotate to a different table to gain a new perspective.
Participation Guidelines
Lean In: These sessions thrive on your input. If you are comfortable, feel free to discuss on your “work-in-progress” thoughts .
Keep it Brief: With limited time, aim for “concise contributions” to ensure everyone at the table has a voice.
Connect: Keep your business cards or digital QR codes ready—these tables are where the best partnerships begin
Note: Seating is first-come, first-served. If a table is full, we encourage you to explore your second-choice topic—you might find an unexpected insight!
Table 1 – Technology & Innovation
Transforming Pharmacovigilance Through Technology: AI, Analytics, and Real-World Evidence
Speakers
HEATHER LEIGH FLANNERY
CEO & Co-Founder
AI MINDSystems Foundation
WILLIAM A. BLUMENTALS
Head of Pharmacoepidemiology, Specialty Care
Sanofi
SPEAKER TBC
Aris Global
GAYATHRI SUBBURAMAN
Senior Director, Global Safety Lead
Menarini Stemline
Table 2 – Audits & Inspections
Audit-Ready Pharmacovigilance: Inspection Preparedness, Compliance, and Best Practices
Speakers
SHALINI PATEL
Sr. Director PV Operations – Pharmacovigilance Center of
Excellence, Moderna
KAPIL BHUTADA
Head of PV Safety Operation & Compliance
Asklepios BioPharmaceutical
Table 3 – Outsourcing & Collaboration
Collaborative Pharmacovigilance: Optimizing Partnerships Across Sponsors, CROs, Sites, and Patients
Speakers
DEANNA MONTES DE OCA
Sr. Director, Global Head of PV Operations Case
Management, Moderna
SANDY (BAUTE) DIAZ
Former Executive Director, North America Patient
Safety Novo Nordisk
Table 4 – Regulatory Landscape
Navigating Global PV Regulations: Updates, Expectations, and Future Directions
Speakers
Table 5 – Risk Management (RMP / REMS)
Next-Generation Risk Management: Evolving RMP and REMS Strategies for Patient Safety
Speakers
Table 6 – Quality, Safety & Signal Detection
Ensuring Quality and Safety in PV: Advanced Approaches to Signal Detection and Risk Evaluation
Speakers
ASHRAF YOUSSEF
Global Senior Medical Director, Post Marketed Products, Global Safety Lead
Takeda Pharmaceuticals
SANDY (BAUTE) DIAZ
Former Executive Director, North America Patient Safety
Novo Nordisk
16:50 – Closing remarks by chairperson and End of day 01 conference
17:00 – 18:15 – Networking Drinks
09:00 - Chairperson opening remarks
Speaker
BEN LOCWIN
VP Board of Directors
SOPPhC (VP, Reliant Life Sciences)
09:10 – AI Agents Transforming Safety, Reporting, and Operations
DATA TO DECISIONS
- Medical AI Agent for Adverse Event Assessment
- From Data to Draft: A Proof-of-Concept Agent for AI – Assisted Aggregate Report Writing
- An AI Agent for Intelligent Navigation of Company Procedures
Speaker
PRIYANKA CHHIKARA
Head of Risk Management, Aggregate Reports & Data
Science, CSL Behring
VINEET SINGH
Head of PV Data Science and Analytics
CSL Behring
09:40 – Product safety reviews – purpose & function
SAFETY
- What to look for in signal evaluation under new EU guidance
- Developing drug safety signals for report quality and content
- Timings for safety review in clinical and post marketed products
- Validation and confirmation of risk and benefits from signal received
- Record keeping for safety review meetings
Speaker
RUDI SCHEERLINCK
Safety Strategy Lead – Oncology
Healthcare Business of Merck
10:10 – Keynote Panel Discussion: Reimagining Global Pharmacovigilance: From Today’s Challenges to Tomorrow’s Solutions
CHALLENGES & OPPORTUNITIES
Moderator
MARIETTE BOERSTOEL-STREEFLAND
SVP, Worldwide Patient Safety Officer
Bristol-Myers Squibb
Panellists
PHILISHA MACK
Sr. Director of Drug Safety, Medical Affairs
Azurity Pharmaceuticals
NICOLE SCHUMACHER-CROW
Continuous Improvement Center of Excellence Head –
Senior Director, Pfizer
MILIND SARDESA
Executive Director, Safety Surveillance, Global Patient
Safety, Dicerna Pharmaceuticals
VASUDEV BHUPATHI
Director – Pharmacovigilance
Moderna
NAMITA JOSHI
Regional PV Head, North America
Sanofi
11:00 – Morning Networking Coffee/Tea & Discussion
11:30 – Real World Data to Real World Evidence
RWD / RWE
- Importance of real-world data for answering regulatory questions
- Benefits and challenges of evidence derived from real world sources
- Real World Evidence: How Does its Use challenge quality and compliance programs?
- Obtaining patient-centric using RWE
- What are complications that will rise by inserting new data source? Breakup in data?
- Identify the challenges involved in incorporating real world evidence into a structured benefit-risk assessment.
JULIE BARBERIO
Director, Pharmacoepidemiology
Sanofi
12:00 – Solution Provider Presentation
For sponsorship opportunities please contact
info.uk@virtueinsight.com
JULIE BARBERIO
Director, Pharmacoepidemiology
Sanofi
12:30 – Networking luncheon
13:30 – Panel Discussion - Transforming Pharmacovigilance Through Technology: AI, Automation, and the Future of Drug Safety. Opportunities, Challenges & Lessons Learned
IMPACT OF TECHNOLOGY
Moderator
HEATHER LEIGH FLANNERY
CEO & Co-Founder
AI MINDSystems Foundation
Panellists
ALTON SARTOR
Medical Director, Patient Safety Physician Digital &
Devices, AstraZeneca
PRIYANKA CHHIKARA
Head of Risk Management, Aggregate Reports & Data
Science, CSL Behring
MICHAEL VON FORSTNER
Chief Scientific Officer
MedGenie
CINTHYA GALICIA QUINTANAR
Senior Manager, Country Safety Lead
Pfizer
14:20 – From Compliance to Excellence: The future of Patient Safety
COMPLIANCE
- Patient Safety, where are we and what has changed lately?
- Fundamentals remain unchanged
- Shift the focus
- Implementation strategy
- Conclusion and take aways
Speaker
MALIN KREITZ
Director of European Operations
Ultragenic Research and Technologies
14:50 – Gene therapy, long-term follow-up, and Inspection readiness
GENE THERAPY / INSPECTION
- Long-term follow-up requirements for Gene therapy
- How to plan inspection readiness activities for Gene therapy.
- Risk Management in Gene Therapy
Speaker
KAPIL BHUTADA
Head of PV Safety Operation & Compliance
Asklepios BioPharmaceutical
15:20 - Afternoon Networking Coffee/Tea & Discussion
15:50 – The round table series
COLLABRATIVE BREAKOUT SESSIONS
Chairperson for all tables
Speaker
BEN LOCWIN
VP Board of Directors
SOPPhC (VP, Reliant Life Sciences)
We have curated 6 distinct roundtable topics, each led by an 2 table speakers. The session is designed for maximum cross-pollination of ideas.
The Selection: Look at the table numbers and topics listed below. Choose the theme most relevant to your interest.
The Format: Each table will host a focused, 60-minute deep dive.
The Flow: Take a seat at your first chosen table. The table speakers will kick off with a brief prompt followed by an open-floor discussion. You have the option to stay put to go deeper or rotate to a different table to gain a new perspective.
Participation Guidelines
Lean In: These sessions thrive on your input. If you are comfortable, feel free to discuss on your “work-in-progress” thoughts .
Keep it Brief: With limited time, aim for “concise contributions” to ensure everyone at the table has a voice.
Connect: Keep your business cards or digital QR codes ready—these tables are where the best partnerships begin
Note: Seating is first-come, first-served. If a table is full, we encourage you to explore your second-choice topic—you might find an unexpected insight!
Table 1 – Technology & Innovation
Transforming Pharmacovigilance Through Technology: AI, Analytics, and Real-World Evidence
Speakers
HEATHER LEIGH FLANNERY
CEO & Co-Founder
AI MINDSystems Foundation
WILLIAM A. BLUMENTALS
Head of Pharmacoepidemiology, Specialty Care
Sanofi
SPEAKER TBC
Aris Global
GAYATHRI SUBBURAMAN
Senior Director, Global Safety Lead
Menarini Stemline
Table 2 – Audits & Inspections
Audit-Ready Pharmacovigilance: Inspection Preparedness, Compliance, and Best Practices
Speakers
KAPIL BHUTADA
Head of PV Safety Operation & Compliance
Asklepios BioPharmaceutical
SHALINI PATEL
Sr. Director PV Operations – Pharmacovigilance Center of
Excellence, Moderna
Table 3 – Outsourcing & Collaboration
Collaborative Pharmacovigilance: Optimizing Partnerships Across Sponsors, CROs, Sites, and Patients
Speakers
DEANNA MONTES DE OCA
Sr. Director, Global Head of PV Operations Case
Management, Moderna
SANDY (BAUTE) DIAZ
Former Executive Director, North America Patient Safety
Novo Nordisk
Table 4 – Regulatory Landscape
Navigating Global PV Regulations: Updates, Expectations, and Future Directions
Speakers
Table 5 – Risk Management (RMP / REMS)
Next-Generation Risk Management: Evolving RMP and REMS Strategies for Patient Safety
Speakers
Table 6 – Quality, Safety & Signal Detection
Ensuring Quality and Safety in PV: Advanced Approaches to Signal Detection and Risk Evaluation
Speakers
ASHRAF YOUSSEF
Global Senior Medical Director, Post Marketed Products, Global
Safety Lead, Takeda Pharmaceuticals
SANDY (BAUTE) DIAZ
Former Executive Director, North America Patient Safety
Novo Nordisk
16:50 – Closing remarks by chairperson and End of day 01 conference
17:00 – 18:15 – Networking Drinks
09:00 - Chairperson opening remarks
Speaker
BEN LOCWIN
VP Board of Directors
SOPPhC (VP, Reliant Life Sciences)
09:10 – Pharmacovigilance with Patients at the Forefront of Drug Safety and Trust
PRIORITISING PATIENTS
- How does the pharma industry approach rigorous pharmacovigilance and safety frameworks and reporting
- What are the public facing safety databases and what are they not (i.e. FAERS)
- How to approach the next generation of drug safety from a truly patient centric perspective
Speaker
WENDY ERLER
SVP Patient Affairs
Sarepta Therapeutics
EDDIE DARTON
VP – Head Global PV & Risk Management
Sarepta Therapeutics
09:50 – Enhancing Quality and Patient Safety Through Pharmacovigilance, Document Control & Policy Governance Integration
SAFETY
- What to look for in signal evaluation under new EU guidance
- Developing drug safety signals for report quality and content
- Timings for safety review in clinical and post marketed products
- Validation and confirmation of risk and benefits from signal received
- Record keeping for safety review meetings
Speaker
FATIMA GHETHAN
Document Control at Executive administration of Quality & Performance
Makkah Health Cluster (Saudi Arabia)
10:20 – Keynote Panel Discussion: Patient-Centric Pharmacovigilance: Shaping the Next Generation of Drug Safety. A New Era of Safety and Trust
PATIENT SAFETY
Moderator
ANUJ PARIKH
Associate Medical Director, Medical Safety
Jazz Pharmaceuticals
Panellists
HARSHA SHETTY
Senior Director, Global Safety Lead & Patient Engagement
CSL Behring
SUSAN WNOROWSKI
Sr. Director, US Medical Information and Patient Safety
Ipsen
KARTHIK MUTHUSAMY
Executive Director, Head of US Patient Safety
Novo Nordisk
TEODORA DOHERTY
Global Medical Safety (GMS), Medical Safety Officer
Janssen R&D
FATIMA GHETHAN
Document Control at Executive administration of Quality &
Performance, Makkah Health Cluster (Saudi Arabia)
11:10 – Morning Networking Coffee/Tea & Discussion
11:30 – Adverse Drug Reactions (ADRs) in Special Populations: Women and Children
- Overview of physiological and pharmacokinetic differences in women and pediatric populations that influence ADR risk
- Common and serious ADR patterns observed in women (e.g., pregnancy, lactation, hormonal factors) and children (e.g., growth and developmental stages)
- Key challenges in detection, reporting, and assessment of ADRs in these special populations
- Strategies to enhance medication safety through tailored prescribing, monitoring, and pharmacovigilance practices
REEM YASIN
Quality Assurance & PV Manager
Hawkary Pharmaceuticals, Kawkab group (Iraq)
12:00 – Solution Provider Presentation
For sponsorship opportunities please contact
info.uk@virtueinsight.com
JULIE BARBERIO
Director, Pharmacoepidemiology
Sanofi
12:30 – Networking luncheon
13:30 – Panel Discussion - From RMPs to REMS: Implementing Effective Next-Generation Risk Management Strategies. Practical Approaches for Modern PV Systems
RISK MANAGEMENT & PLANNING
Moderator
KAL ELHOREGY
Director, Risk Evaluation and Mitigation Strategy (REMS) Programs
Amneal Pharmaceuticals
Panellists
MICHELE COIRO
Director, US REMS Strategy & Submissions
Bristol-Myers Squibb
ALLISON CONCANNON
Director, Global Patient Safety, Americas Lead
Ipsen
Global Head of Medical Safety
REEM YASIN
Quality Assurance & PV Manager
Hawkary Pharmaceuticals, Kawkab group (Iraq)
MICHAEL VON FORSTNER
Chief Scientific Officer
MedGenie
CINTHYA GALICIA QUINTANAR
Senior Manager, Country Safety Lead
Pfizer
14:20 – Panel Discussion: Regulatory Pathways to Patient Safety: How Regulatory Changes Are Reshaping PV?. What’s Next in PV Regulations? Trends, Updates, and the Road Ahead
REGULATORY UPDATE
Moderator
BEN LOCWIN
VP Board of Directors
SOPPhC (VP, Reliant Life Sciences)
Panellists
ALTON SARTOR
Medical Director, Patient Safety Physician Digital &
Devices, AstraZeneca
PRIYANKA CHHIKARA
Head of Risk Management, Aggregate Reports & Data
Science, CSL Behring
MICHAEL VON FORSTNER
Chief Scientific Officer
MedGenie
CINTHYA GALICIA QUINTANAR
Senior Manager, Country Safety Lead
Pfizer
15:00 - Afternoon Networking Tea/Coffee & End of conference
09:00 - Chairperson opening remarks
Speaker
BEN LOCWIN
VP Board of Directors
SOPPhC (VP, Reliant Life Sciences)
09:10 – Pharmacovigilance with Patients at the Forefront of Drug Safety and Trust
PRIORITISING PATIENTS
- How does the pharma industry approach rigorous pharmacovigilance and safety frameworks and reporting
- What are the public facing safety databases and what are they not (i.e. FAERS)
- How to approach the next generation of drug safety from a truly patient centric perspective
Speaker
WENDY ERLER
SVP Patient Affairs
Sarepta Therapeutics
EDDIE DARTON
VP – Head Global PV & Risk Management
Sarepta Therapeutics
09:50 – Enhancing Quality and Patient Safety Through Pharmacovigilance, Document Control & Policy Governance Integration
SAFETY
- What to look for in signal evaluation under new EU guidance
- Developing drug safety signals for report quality and content
- Timings for safety review in clinical and post marketed products
- Validation and confirmation of risk and benefits from signal received
- Record keeping for safety review meetings
Speaker
FATIMA GHETHAN
Document Control at Executive administration of Quality & Performance
Makkah Health Cluster (Saudi Arabia)
10:20 – Keynote Panel Discussion: Patient-Centric Pharmacovigilance: Shaping the Next Generation of Drug Safety. A New Era of Safety and Trust
PATIENT SAFETY
Moderator
ANUJ PARIKH
Associate Medical Director, Medical Safety
Jazz Pharmaceuticals
Panellists
HARSHA SHETTY
Senior Director, Global Safety Lead & Patient Engagement
CSL Behring
SUSAN WNOROWSKI
Sr. Director, US Medical Information and Patient Safety
Ipsen
KARTHIK MUTHUSAMY
Executive Director, Head of US Patient Safety
Novo Nordisk
TEODORA DOHERTY
Global Medical Safety (GMS), Medical Safety Officer
Janssen R&D
FATIMA GHETHAN
Document Control at Executive administration of Quality &
Performance, Makkah Health Cluster (Saudi Arabia)
11:10 – Morning Networking Coffee/Tea & Discussion
11:30 – Adverse Drug Reactions (ADRs) in Special Populations: Women and Children
- Overview of physiological and pharmacokinetic differences in women and pediatric populations that influence ADR risk
- Common and serious ADR patterns observed in women (e.g., pregnancy, lactation, hormonal factors) and children (e.g., growth and developmental stages)
- Key challenges in detection, reporting, and assessment of ADRs in these special populations
- Strategies to enhance medication safety through tailored prescribing, monitoring, and pharmacovigilance practices
REEM YASIN
Quality Assurance & PV Manager
Hawkary Pharmaceuticals, Kawkab group (Iraq)
12:00 – Solution Provider Presentation
For sponsorship opportunities please contact
info.uk@virtueinsight.com
JULIE BARBERIO
Director, Pharmacoepidemiology
Sanofi
12:30 – Networking luncheon
13:30 – Panel Discussion - From RMPs to REMS: Implementing Effective Next-Generation Risk Management Strategies. Practical Approaches for Modern PV Systems
RISK MANAGEMENT & PLANNING
Moderator
KAL ELHOREGY
Director, Risk Evaluation and Mitigation Strategy (REMS) Programs
Amneal Pharmaceuticals
Panellists
MICHELE COIRO
Director, US REMS Strategy & Submissions
Bristol-Myers Squibb
ALLISON CONCANNON
Director, Global Patient Safety, Americas Lead
Ipsen
Global Head of Medical Safety
REEM YASIN
Quality Assurance & PV Manager
Hawkary Pharmaceuticals, Kawkab group (Iraq)
MICHAEL VON FORSTNER
Chief Scientific Officer
MedGenie
CINTHYA GALICIA QUINTANAR
Senior Manager, Country Safety Lead
Pfizer
14:20 – Panel Discussion: Regulatory Pathways to Patient Safety: How Regulatory Changes Are Reshaping PV?. What’s Next in PV Regulations? Trends, Updates, and the Road Ahead
REGULATORY UPDATE
Moderator
BEN LOCWIN
VP Board of Directors
SOPPhC (VP, Reliant Life Sciences)
Panellists
ALTON SARTOR
Medical Director, Patient Safety Physician Digital &
Devices, AstraZeneca
PRIYANKA CHHIKARA
Head of Risk Management, Aggregate Reports & Data
Science, CSL Behring
MICHAEL VON FORSTNER
Chief Scientific Officer
MedGenie
CINTHYA GALICIA QUINTANAR
Senior Manager, Country Safety Lead
Pfizer
15:00 - Afternoon Networking Tea/Coffee & End of conference
Download Brochure
Event Sponsors
We wouldn’t be able to host our conferences without help from these amazing companies. A huge thanks to all our sponsors and partners!
Platinum Sponsor
Bronze Sponsor
Conceptualized by
- Phone:+91 44 42108101
- Email:info@virtueinsight.com
Supported by
- Phone:+1 628-600-1786
- Email:ebhelp@eventbrite.com
- Phone:+91 89250 31783
- Email:info@allconferencealert.com
Event Testimonials
A huge thanks to all our sponsors, attendees and partners!
“Thank you Siddhaarth! You and the team did an outstanding job once again! Appreciate everything Virtue Insight does to promote PV. Excellent speakers and panels”
“Thank you for a great conference. What a pleasant surprise to win the mini”
“I enjoyed the venue (Waltham Conference Center), and think it would be a good fit for a meeting of this size. ”
“A huge compliment to the organizers! The event was very well researched and organized. The speakers represented leading organizations and addressed the most recent questions in the field, providing insights in current developments and meaningful solution approaches. The conference provided excellent opportunities to discuss recent developments with top experts and build impactful professional relationships. Overall, the conference was very useful and a joy to attend, also due to the selection of an easy to reach venue in an environment of biomedical research excellence and quality.”
Booking Details
We are currently in process of moving our payment gateway. Our online booking option will be coming soon. In the mean time please use below secure payment link to confirm your participation.
Super Early Bird Price (Valid till 27 March)
For 1 Delegate – $899
Group Discount – $1798 (3 Delegates for the price of 2)
Venue details
The venue is easily accessible, well-equipped with modern amenities, and offers a comfortable, professional setting for all attendees.
Venue
Boston
USA
13869 Park Center Rd,
Herndon, VA 20171,
United States
+1 703-478-2900
Venue – Boston, USA
13869 Park Center Rd,
Herndon, VA 20171,
United States
+1 703-478-2900





